Zai Lab Announces Upcoming Presentation at February Investor Conference

Rhea-AI Summary

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced their participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 8:40 a.m. ET. This virtual investor conference will feature a fireside chat with company management.

Investors can access the live webcast and an archived replay for 90 days on Zai Lab's website under the “Events & Presentations” section. Zai Lab focuses on developing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience while building partnerships to enhance their global biopharmaceutical pipeline.

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conference in February:

11th Annual SVB Leerink Global Healthcare Conference
Fireside Chat: Thursday, February 17, 2022, 8:40 a.m. ET

Webcast link of the 11th Annual SVB Leerink Global Healthcare Conference will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Investor Relations: Ron Aldridge / Lina Zhang
+1 (781) 434-8465 / +86 136 8257 6943
ronald.aldridge@zailaboratory.com / lina.zhang@zailaboratory.com 

Media: Danielle Halstrom / Xiaoyu Chen
+1 (215) 280-3898 / +86 185 0015 5011
danielle.halstrom@zailaboratory.com / xiaoyu.chen@zailaboratory.com  

Zai Lab Limited

Source: Zai Lab Limited

FAQ

When is Zai Lab presenting at the 11th Annual SVB Leerink Global Healthcare Conference?

Zai Lab is presenting at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 8:40 a.m. ET.

How can I access the Zai Lab conference presentation?

You can access the Zai Lab conference presentation via the live webcast link available in the “Events & Presentations” section on their website.

What is the focus of Zai Lab as a biopharmaceutical company?

Zai Lab focuses on developing innovative therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience.

Where can I find more information about Zai Lab's investor relations?

More information about Zai Lab's investor relations can be found on their official website under the Investor Relations section.

Is there an archive available for the Zai Lab presentation after the event?

Yes, an archived replay of the Zai Lab presentation will be available for 90 days following the event.